Saved in:
Bibliographic Details
Main Authors: Pauline Mazilier, Laurence Dedeken, Eleonore Powis, Pierluigi Calò, Stéphane Luyckx, Laure Kornreich, Safiatou Diallo, Adriano Salaroli, Christine Devalck
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Online Access:https://onlinelibrary.wiley.com/doi/10.1002/pbc.32071
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867002129903779841
author Pauline Mazilier
Laurence Dedeken
Eleonore Powis
Pierluigi Calò
Stéphane Luyckx
Laure Kornreich
Safiatou Diallo
Adriano Salaroli
Christine Devalck
author_facet Pauline Mazilier
Laurence Dedeken
Eleonore Powis
Pierluigi Calò
Stéphane Luyckx
Laure Kornreich
Safiatou Diallo
Adriano Salaroli
Christine Devalck
Pauline Mazilier
Laurence Dedeken
Eleonore Powis
Pierluigi Calò
Stéphane Luyckx
Laure Kornreich
Safiatou Diallo
Adriano Salaroli
Christine Devalck
collection Wiley Open Access
contents Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation in Children: A Single Pediatric Center Experience Pauline Mazilier Laurence Dedeken Eleonore Powis Pierluigi Calò Stéphane Luyckx Laure Kornreich Safiatou Diallo Adriano Salaroli Christine Devalck Pediatric Blood & Cancer ABSTRACT Background Hemorrhagic cystitis (HC) is a frequent and potentially severe complication following hematopoietic stem cell transplantation (HSCT) in children. It significantly affects the quality of life and prolongs hospitalization. Despite its frequency, no standardized management guidelines exist. This study aimed to describe the characteristics, risk factors, and treatments of HC in a pediatric HSCT population. Methods We conducted a retrospective single‐center study including all pediatric patients who underwent allogeneic HSCT between January 2007 and December 2022. HC was defined and graded according to the European Conference on Infections in Leukaemia (ECIL) guidelines. We analyzed risk factors, BK virus (BKV) viruria, treatments, and outcomes. Results HC occurred in 24 patients (14.7%), with a median onset at 27.5 days post‐HSCT. Acute graft‐versus‐host disease (aGVHD) was significantly associated with HC occurrence (45.8% vs. 19.4%, p = 0.01), particularly in its severe forms ( p = 0.007). BKV was detected in 66.7% of HC cases. Viral load in urine was not significantly associated with HC severity or duration. All patients received supportive care; cidofovir was used in 79.2%, with increasing frequency in higher grade HC. Severe cases required multimodal management, including intravesical installations, hyperbaric oxygen therapy (HBO; 37.5%), and arterial embolization (all Grade 4 cases). No deaths were directly attributed to HC. Conclusions HC remains a significant and morbid complication after pediatric HSCT. Our findings highlight the need for early identification of high‐risk patients and access to timely, multidisciplinary interventions. Multicenter prospective studies are essential to standardize care and improve outcomes in this vulnerable population. 10.1002/pbc.32071 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1002/pbc.32071
format Artículo Open Access
id wiley_oa_10_1002_pbc_32071
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation in Children: A Single Pediatric Center Experience
Pauline Mazilier
Laurence Dedeken
Eleonore Powis
Pierluigi Calò
Stéphane Luyckx
Laure Kornreich
Safiatou Diallo
Adriano Salaroli
Christine Devalck
Pediatric Blood & Cancer
Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation in Children: A Single Pediatric Center Experience Pauline Mazilier Laurence Dedeken Eleonore Powis Pierluigi Calò Stéphane Luyckx Laure Kornreich Safiatou Diallo Adriano Salaroli Christine Devalck Pediatric Blood & Cancer ABSTRACT Background Hemorrhagic cystitis (HC) is a frequent and potentially severe complication following hematopoietic stem cell transplantation (HSCT) in children. It significantly affects the quality of life and prolongs hospitalization. Despite its frequency, no standardized management guidelines exist. This study aimed to describe the characteristics, risk factors, and treatments of HC in a pediatric HSCT population. Methods We conducted a retrospective single‐center study including all pediatric patients who underwent allogeneic HSCT between January 2007 and December 2022. HC was defined and graded according to the European Conference on Infections in Leukaemia (ECIL) guidelines. We analyzed risk factors, BK virus (BKV) viruria, treatments, and outcomes. Results HC occurred in 24 patients (14.7%), with a median onset at 27.5 days post‐HSCT. Acute graft‐versus‐host disease (aGVHD) was significantly associated with HC occurrence (45.8% vs. 19.4%, p = 0.01), particularly in its severe forms ( p = 0.007). BKV was detected in 66.7% of HC cases. Viral load in urine was not significantly associated with HC severity or duration. All patients received supportive care; cidofovir was used in 79.2%, with increasing frequency in higher grade HC. Severe cases required multimodal management, including intravesical installations, hyperbaric oxygen therapy (HBO; 37.5%), and arterial embolization (all Grade 4 cases). No deaths were directly attributed to HC. Conclusions HC remains a significant and morbid complication after pediatric HSCT. Our findings highlight the need for early identification of high‐risk patients and access to timely, multidisciplinary interventions. Multicenter prospective studies are essential to standardize care and improve outcomes in this vulnerable population. 10.1002/pbc.32071 http://creativecommons.org/licenses/by-nc/4.0/
title Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation in Children: A Single Pediatric Center Experience
topic Pediatric Blood & Cancer
url https://onlinelibrary.wiley.com/doi/10.1002/pbc.32071